The global regulatory landscape is undergoing important changes: individual regulatory bodies around the world are introducing initiatives to enhance diversity in clinical trials. Differing regulatory mandates are not new for clinical development programs, but effectively navigating diversity guidance will require a comprehensive understanding not just of the global regulatory landscape but also why these initiatives are needed and what they hope to achieve.